Koutech Secures Tens of Millions in Series A+ Funding Within Just Three Months, Led Solely by Temasek

VCBeat learned that recently, KouTech, a company specializing in ultra-micro and high-precision surgical robot platforms, has secured millions of dollars in its Series A+ round of financing within less than three months after completing its previous round.This round of financing was exclusively invested by Temasek Holdings. The funds will mainly be used for the company's overseas registration, product development, team expansion, etc. VCBeat continues to serve as the exclusive financial advisor for the company's financing.

KouTech is an innovative surgical robot platform company that focuses on minimally invasive microscopic technology to expand the boundaries of surgery. In recent years, continuous iterations in surgical instruments have indeed enabled wider application of minimally invasive surgeries, giving rise to surgical robots. However, even so, narrow spaces crisscrossed with blood vessels and nerves remain no-go zones for surgeons. Through relentless efforts, KouTech has already achieved leadership in this cutting-edge field.

KouTech began collaborating with medical giants in Japan and the United States as early as 2011. After gradually gaining insights into market development trends and technical gaps, KouTech has become the first company in the industry to successfully achieve full-process non-tremor operation after more than a decade of technological accumulation. While steadily advancing the research and development and certification of general-purpose microsurgical robots, ophthalmic surgical robots, and trans-endoscopic robots in China, it will also establish a U.S. branch to simultaneously promote FDA registration in the United States.This inflow of funds will undoubtedly accelerate the process of product registration both in China and overseas.

Regarding this round of financing, the KouTech team stated:"Thrilled to receive strong support from Temasek, whose capital injection and overseas market empowerment will undoubtedly accelerate the commercialization and internationalization of our products, helping us enter the U.S. and European markets more swiftly and robustly. In the future, while expanding procedural applications, the company will continue to deepen its expertise and simultaneously enhance its super-value technologies, including further advancing intelligent upgrades and comprehensive system network data analysis and processing, gradually growing into the 'Da Vinci' of the super-micro field!"

KouTech's developed microsurgical robot is the most refined surgical robot globally, featuring delicate and long-lasting consumables. Its master-slave operated soft tissue robot, with multiple degrees of freedom, is compact and flexible, allowing for rapid deployment in various operating rooms with minimal setup requirements. The wrist-like structure at the tip of the instrument has a diameter of less than 3mm, also the smallest globally, capable of performing anastomosis on 0.3mm blood vessels and lymphatic vessels.

In the field of microsurgical robotics, currently only the Symani system developed by Italian company Medical Micro Instruments and the MUSA system developed by Dutch company Microsure have obtained CE certification. Compared to these two companies, KouTech has obvious advantages, such asRobots can perform high spatial dimension operations in more refined scenarios, with more reusable cycles and stronger anti-tremor capabilities. Additionally, the drive belt of the front-end clamp eliminates the risk of blockage or jamming of the power mechanism due to knotting.

It is precisely this product, which has achieved a breakthrough worldwide and occupied the technological high ground, that can truly expand the boundaries of surgery and fully leverage the core value of robotics. Coming from clinical practice and returning to clinical practice, developing a product that genuinely addresses clinical needs is the belief upheld by the company. During the product development process, the company actively communicated with clinicians, continuously adjusting and optimizing based on feedback until it launched such a highly disruptive and clinically valuable product that benefits all humanity, fulfilling the earnest hopes of clinicians.

Focusing on the global market, with a high degree of integration between medicine and engineering, KouTech is bound to become an even more resolute and steady force in the field of super-micro technology under the support of new capital, emerging as a prominent Chinese power in the spotlight!

As the investor in this round, the Temasek team stated"KouTech team has an international perspective and more than ten years of cooperation with well-known medical device manufacturers in the United States, Japan, and other countries. Based on Japanese precision machining technology and supported by China's strong clinical expert resources, the company has grown into the first Chinese enterprise to independently develop master-slave microsurgery robots under the virtuous cycle of medical-engineering integration. The company’s innovative precision machining capabilities, fully independent intellectual property rights, and forward-thinking overseas layout align perfectly with Temasek’s investment logic. Therefore, the support at the capital level is only the beginning. In fields such as innovative medical device exports where Temasek excels, it will further empower the company. The team is very honored to accompany outstanding enterprises like KouTech in their growth and witness their development and expansion!"

Sylvia Siu, Managing Director of Life Capital, the exclusive financial advisor for this round, stated"Since its establishment, KouTech has always stayed true to its original mission and remained grounded. Not only has it inherited Japan's precision processing technology in the field of medical robotics, but its founder, Mr. Watanabe, has also been deeply influenced by the craftsmanship spirit of meticulously refining products. He has built a team that similarly 'never gives up the opportunity to improve product quality from 99% to 99.99%.' We value and firmly believe that only companies committed to continuous improvement in both technology and attitude can truly achieve disruption. We look forward to KouTech, with microscopy as its entry point, continuing to cultivate deeply, striving daily, and gradually excelling!"

Temasek is a global investment company headquartered in Singapore, with 13 offices across 9 countries. Temasek defines its three key roles as an investor, institution, and steward of assets, shaping a philosophy and mission centered on pursuing excellence, fulfilling purpose, and creating value for generations. Temasek provides capital to drive growth and is committed to empowering solutions to address major global challenges. Sustainability lies at the core of all Temasek's actions. Temasek actively seeks sustainable solutions to overcome current and future challenges, seize investment opportunities, and help build a more sustainable future for broader communities.

Since its establishment in 2017, Life Capital has adhered to the service philosophy of "customer success, co-creation and win-win," focusing heavily on the life sciences and healthcare industry. It persists in offering three major investment banking products—private equity financing, mergers and acquisitions, private equity investment—with extreme professionalism, along with profound industrial value-added services. It has deeply cultivated several cutting-edge niche areas such as innovative drugs, biotechnology, medical devices, consumer healthcare, and smart healthcare. To date, it has helped over 50 healthcare companies complete private equity financing, with a total transaction value exceeding 30 billion RMB.